GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +28.6% ·
share flow +14.4% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | -3 | 40.75M | $985.52M | +5 | −8 |
| Q1 2026 | 84 | +11 | 37.29M | $613.27M | +14 | −3 |
| Q4 2025 | 73 | -1 | 26.21M | $411.01M | +1 | −2 |
| Q3 2025 | 18 | +2 | 20.02M | $148.32M | +2 | — |
| Q2 2025 | 13 | +1 | 20.51M | $92.50M | +1 | — |
| Q1 2025 | 9 | -3 | 9.96M | $46.20M | +1 | −4 |
| Q4 2024 | 12 | +2 | 11.82M | $82.01M | +2 | — |
| Q3 2024 | 9 | +2 | 9.48M | $50.23M | +2 | — |
| Q2 2024 | 7 | — | 8.29M | $30.99M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.60M | +10.4% | $34.99M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 6.60M | +10.4% | $34.99M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 1.16M | +16.4% | $6.14M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.04M | +23.3% | $5.54M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.04M | +23.3% | $5.54M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 218.70K | -14.1% | $1.16M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 217.00K | +30.2% | $1.15M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 217.00K | +30.2% | $1.15M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Marshall Wace ✦ | 173.85K | New | $921,400 | 0.0% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 30.62K | +46.3% | $162,291 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 18.29K | -21.9% | $96,942 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 13.50K | New | $71,550 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $921,400 | 0.0% |
| Two Sigma Investments | $71,550 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 86.88M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.